The European Bank for Reconstruction and Development (EBRD) is investing €24 million in Famar, supporting the acquisition of the pharmaceutical company alongside MidEuropa and other investors.

According to the announcement, this investment is expected to support the growth vision for Famar, including the expansion of its production and research and development (R&D) facilities in Greece.

Famar is among the leading pharmaceutical CDMOs, focusing on the production and distribution of a wide range of pharmaceuticals, healthcare products, and cosmetics. It is recalled that it is headquartered in Greece and has production facilities in Greece, Italy, and Spain.

Under the new management, Famar intends to make significant investments in Greece, including for the expansion of production and R&D capabilities as the company continues its operations.

Since 2015, when it started operating in Greece, the EBRD has invested at least €7.9 billion in 115 projects ranging from the financial sector to energy and infrastructure.